tiprankstipranks
Advertisement
Advertisement
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion
PremiumCompany AnnouncementsARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion
11d ago
ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)
Premium
The Fly
ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)
11d ago
ARS Pharmaceuticals Appoints Donn Casale as New President
Premium
Company Announcements
ARS Pharmaceuticals Appoints Donn Casale as New President
13d ago
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
PremiumThe FlyARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
2M ago
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
Premium
TipRanks Newswire
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
2M ago
Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
Premium
The Fly
Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
3M ago
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
PremiumRatingsARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
5M ago
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
Premium
Ratings
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
5M ago
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
Premium
The Fly
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100